Kornimate/medical-research-clean huggingface dataset:
pharmacokinetic and efficacy of sqv/r 1500/100 plus tenofovir/emtricitabine 300/200 mg

Conditions: Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID

Summary: pharmacokinetic and long term efficacy of tdf sqv film coated tablet 1500/100mg once daily plus tdf/ftc300/200mg once daily.

this study will be performed in patients who were previously treated with sqv /r 1000/100mg twice daily or lopinavir/r plus tdf/ftc once daily as part of the gemini study. after 48 weeks of the study, the patients will be treated with sqv film coated tablet 1500/100mg once daily plus tdf/ftc300/200mg once daily with good cd4 and vl outcomes. in this study, we would like to evaluate the once-daily dosing of sqv using sqv- sqv film coated tablet 1500/ritonavir 100mg in combination with tdf/ftc300/200mg once daily. we believe that the pk parameters of sqv given at 1500mg daily will be equivalent to the 1000mg twice daily dosing when combined with rtv and tdf/ftc300/200mg od, and that the once daily regimen will have better safety, tolerability profile than the twice daily regimen while maintaining good cd4 and vl outcome

Eligibility criteria:
inclusion criteria: 1. written informed consent 2. all adults hiv patients previously included in the gemini study and are currently enrolled in hiv-nat 006 and treated with sqv /r 1500/100 mg od plus tenofovir/emtricitabine (tdf/ftc) 300/200 mg once daily exclusion criteria: 1. inability to understand the nature and extent of the study and the procedures required. 2. alt/ ast more than 5x upper limit 3. relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion. 4. use of concomitant medication that may interfere with the pharmacokinetics of saquinavir, ritonavir, tenofovir or emtricitabine 5. history of sensitivity/idiosyncrasy to the drug or chemically related compounds which may be employed in the study. 6. active drug abuse

Keywords: saquinavir/ritonavir 1500/100 mg once daily
augmented reality distraction for reducing pain in pediatric dental procedures

Conditions: Dental Anxiety

Summary: this randomized controlled trial evaluates the effectiveness of augmented reality (ar) as a distraction technique to reduce procedural pain and anxiety in children aged 6-10 undergoing primary tooth extraction. participants will be randomly assigned to receive either ar distraction via vr goggles or standard tell-show-do behavior management during local anesthesia administration and extraction.

pain and anxiety are major challenges in pediatric dental care. ar presents an innovative, non-pharmacological technique to manage procedural distress. the study compares ar distraction versus conventional behavioral guidance in terms of self-reported pain (wong-baker faces), dental anxiety (cfss-ds), and physiological anxiety (heart rate monitoring). a double-blind design will ensure unbiased outcomes.

Eligibility criteria:
inclusion criteria: * children aged 6-10 years indicated for anterior primary tooth extraction no previous exposure to local anesthesia exclusion criteria: * medically compromised children children with cognitive or communication impairments children who underwent similar treatment within the past 3 months
an evaluation of lasik, smile and prk surgery in physicians

Conditions: Nearsightedness; Farsightedness; Astigmatism

Summary: the principle investigator is evaluating self-reported quality of vision and quality of life in physicians undergoing lasik, smile and prk surgery.

the participants will have a comprehensive eye examination once they express an interest in the study. this includes a slit lamp examination of the front of the eye and a dilated fundoscopic examination of the back of the eye. if there is any pathology noted that would exclude the participant from the study, then the investigator will inform the participant and make an appropriate referral. this is standard practice for laser in situ keratomileusis (lasik) surgery, small incision lenticule extraction (smile) and photorefractive keratectomy (prk) surgery. if the participant is deemed appropriate for the study after a comprehensive examination including computerized videokeratography, then the participant can be enrolled. these exams are also standard practice for lasik, smile and prk surgery. the quality of vision (qov) questionnaire will be administered following the pre-operative visit during which participants are enrolled and then at the three-month and twelve-month post- op visits before the participants are seen by the principle investigator. the questionnaire is the study intervention. the participant will undergo bilateral simultaneous lasik eye surgery, smile or prk surgery. the participants will be seen pre-operatively, on the day of surgery, post op day one, one month, three months, and twelve-months as part of the study. participants may also be seen more frequently if required from a medical standpoint. the participant will receive topical antibiotics in each eye for one week following the procedure. lasik treated eyes will receive pred forte 1% ophthalmic drops for one week to four weeks after treatment. all of this is within the usual and customary standard of care for the treatment of patients undergoing lasik, smile and prk surgery.

Eligibility criteria:
inclusion criteria. * 21 years or older. * a physician or medical student. * have the ability to give informed consent. * speak and read english fluently. * have not previously had any form of refractive surgery, including prior lasik or cataract surgery. * may benefit from increased spectacle independence. * have been determined to be a good candidate for the lasik, smile or prk procedure based on the investigator's assessment of medical and ophthalmic health, general cognitive function, and physical and social limitations. * have a treatment target of bilateral emmetropia. * express willingness and potential ability to return for all follow-up examinations through the 12-month follow-up exam under the care of the treating investigator. * are not enrolled in any other research study. exclusion criteria. * subjects under the age of 21. * patients with excessively thin corneas. * patients with topographic evidence of keratoconus. * patients with ectatic eye disorders. * patients with autoimmune diseases. * patients who are pregnant or nursing.
trial of pemetrexed or pemetrexed with gemcitabine for patients with advanced lung cancer who are not eligible for platinum-based chemotherapy and have not previously been treated with chemotherapy

Conditions: Non-Small Cell Lung Cancer

Summary: this study is for elderly patients who haven't been given prior chemotherapy or for patients who cannot be treated with platinum based chemotherapy. the patients who are eligible for this study will have been diagnosed with advanced or metastatic non-small cell lung cancer. the patients will be randomly assigned to one of two treatment options: single agent pemetrexed or single agent pemetrexed with single agent gemcitabine following right after the pemetrexed treatment.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed nsclc not amenable to surgery or radiotherapy of curative intent * locally advanced or metastatic stage iiib (with n3 supraclavicular or t4 for pleural effusion) or iv nsclc * no prior chemotherapy * measurable disease according to response evaluation criteria in solid tumors (recist) criteria (therasse et al. 2000) * men and women greater than or equal to 70 years of age or patients who, in the investigator's opinion, are not eligible for platinum-based chemotherapy exclusion criteria: * have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry * have symptomatic brain metastases * have a history or presence of other malignancy except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years before without recurrence (excluding melanoma, breast cancer and hypernephroma) * are unable to interrupt therapy with aspirin or other nonsteroidal anti-inflammatory drugs (nsaids) such as naproxen, piroxicam, diflunisal, or nabumetone around each dose of pemetrexed (5 days for short-acting or 8 days for long acting preparations) * are unable or unwilling to take steroids * are unable or unwilling to take folic acid or vitamin b12 supplementation * have clinically detectable (by physical examination) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry * have other serious concomitant illness or medical conditions according to investigator criteria, including but not limited to the following: * congestive heart failure or angina pectoris, except if it is medically controlled * previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension, or arrhythmias * active infection requiring iv antibiotics * active ulcer, unstable diabetes mellitus, or other contra-indication to corticotherapy * superior vena cava syndrome
influence of respiratory muscle training in elderly hypertensive women with respiratory muscle weakness

Conditions: Hypertension

Summary: this study aims to evaluate pulmonary function and respiratory muscle strength in a group of elderly women with hypertension before and after a respiratory muscle training.

it is a respiratory muscle training using the threshold for 5 weeks, with a load of 30% of maximal inspiratory pressure obtained in manometer for 30 minutes daily. furthermore, the assessment includes: test 6-minute walk, the quality of life questionnaire, minichal, the ipaq short version, manometer and spirometry.

Eligibility criteria:
inclusion criteria: * diagnosis of hypertension controlled by antihypertensive; * aged between 60 and 80 years; * absence of dementia or cognitive impairments that limit tests; * absence of recent myocardial infarction; * absence of musculoskeletal limitations that limit tests; * availability of time on training days. exclusion criteria: * clinical instability; * inability to perform any test.

Keywords: hypertension
cataract surgery in patients with advanced age

Conditions: Cataract Senile

Summary: this study evaluates and compares clinical outcomes of \< 85 and ≥ 85 year old patients who underwent cataract surgeries.

the medical records of patients who were underwent cataract surgery between january 2014 and october 2017 were investigated retrospectively and patients 65 years and older were recruited. two groups were made according to age: group1 composed of patients age range between 65 and 85 years and group 2 composed of patients 85 years and older. gender, presence of diabetes mellitus (dm), hypertension (ht), drug use were noted. the results of best corrected visual acuity (bcva) converted to logmar, intraocular pressure (iop) before and 3 months after operation, biomicroscopic and fundus examinations were investigated. additional ocular diseases such as glaucoma, age related macular degeneration (amd), pseudoexfoliation syndrome, retinopathies and maculopathies related to systemic diseases were noted. pupil dilation properties were also noted as poor, mid or full pupil dilation. cataract surgery techniques such as phacoemulsification, extra- and intracapsular lens extractions, peroperative complications, intracameral drug use were investigated. these aforementioned outcomes evaluated and compared between groups.

Eligibility criteria:
inclusion criteria: * patients aged 65 years and older patients who underwent cataract surgery exclusion criteria: * patients aged below 65 years who underwent cataract surgery

Keywords: geriatry cataract surgery advanced age
the norwegian atrial fibrillation self-screening

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is common, increases the risk of mortality, stroke and heart failure, and portending significant burden to patients, societal health and health economy. one of three af cases are undiagnosed. several methods for detection of af exist, but most of them have major limitations and are associated with resource-demanding diagnostic workup in the speciality health care services.

this randomized clinical trial will evaluate whether self-screening for af with the ecg247 patch monitor will reduce af-related morbidity.

Eligibility criteria:
inclusion criteria: * age ≥65 years and minimum one other risk factor for stroke according to the cha2ds2-vasc risk score: age ≥75 years, diabetes, heart failure, hypertension, previous stroke/tia and/or vascular disease * informed consent for participation exclusion criteria: * history of af (self-reported) * use of anticoagulation therapy * pacemaker/crt device * no smart phone
effectıveness of the sexually transmıtted dıseases educatıon program for adolescents

Conditions: Sexually Transmitted Diseases

Summary: the world health organization has defined the period between the ages of 10-19 as adolescence, 15-24 years as youth and 10-24 years as youth period. adolescence is divided into 3 periods: early adolescence (10-13 years), middle adolescence (14-16 years) and late adolescence (17-21 years). hiv virus and aids, which have become a problem among sexually transmitted diseases all over the world, have increased the importance of controlling sexually transmitted diseases. there is a strong correlation between the spread of stds through traditional means and the transmission of hiv; and sexually transmitted diseases have been found to increase the risk of sexual transmission of hiv. according to who data, 340 million treatable stds, millions of incurable stds and 5 million hiv cases occur worldwide each year.

people in the 15-49 age group who are sexually active are the most likely to contract sexually transmitted diseases. the prevalence of stds is higher in developing countries than in developed countries. these diseases are among the top 5 etiologic factors that cause loss of years of "healthy productive life" in developing countries. as in other countries, sexually transmitted diseases are of great importance in terms of complications and sequelae in turkey one out of 20 young people is infected with stds every year. in our country, the age of sexual maturation has shifted earlier. in addition, the age of sexual experience of young people has also shifted earlier. young people's understanding of freedom and their inability to access fp methods whenever they want negatively affect their sexual health behaviors. impact on society stds cause a lot of economic and social damage to society. stds may disrupt the normal functioning of family, community and health institutions and leave these institutions under a heavy economic burden. stds reduce the productivity of men and women at the most productive ages of their lives. in addition, when outbreaks of these infections are not controlled, the costs to society will increase. translated with deepl.com (free version)

Eligibility criteria:
inclusion criteria: * at a foundation university located within the borders of istanbul province 1.2.3. and 4th grade students exclusion criteria: -

Keywords: adolescent sexually transmitted diseases education
safety and efficacy of aerofact in preterm infants with respiratory distress syndrome

Conditions: Respiratory Distress Syndrome; Pre-term Infants

Summary: this is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with rds who are treated with aerofact and ncpap/niv to subjects treated with ncpap/niv alone (sham). in part 1, subjects will be followed until they reach 40 weeks post-menstrual age (pma) or are discharged from the nicu, whichever comes first. in part 2, subjects will undergo post-term follow-up through 12 months corrected age.


Eligibility criteria:
inclusion criteria: 1. inborn at the study site's hospital (i.e., not transferred from another hospital following delivery) 2. gestational age at birth of 26 through 31 weeks (260/7 through 316/7 weeks pma) 3. birth weight appropriate for gestational age (aga, weight 3rd to 97th percentile on fenton growth curve) 4. birth weight ≤ 2000 grams 5. post-natal age 1 to 24 hours at randomization 6. on ncpap or niv with rss = 1.4 - 2.0 to maintain spo2 90-95% at randomization. rss is calculated as (ncpap cm h2o) × (fio2) or as (niv mean airway pressure cm h2o) × (fio2). 7. fio2 ≥ 0.23 at randomization 8. ncpap or mpaw ≥ 6 cm h2o at randomization 9. chest radiograph (cxr) or lung ultrasound compatible with rds prior to randomization exclusion criteria: 1. on sipap®, ram® cannula, or high flow nasal cannula (hfnc) (\> 2 liters per minute \[lpm\]) at the time of randomization 2. prior instillation of surfactant 3. premature rupture of membranes (prom) occurring \> 14 days before birth 4. significant congenital/chromosomal anomaly (e.g., pierre robin syndrome, clinically significant congenital heart disease, or trisomy) 5. pneumothorax 6. other etiologies of respiratory distress 7. enrollment in another interventional study with similar efficacy endpoints 8. apgar score at 5 min of 0-3 9. prior cardiopulmonary resuscitation (cpr) or epinephrine 10. base deficit \> 15 meq/l on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. note that arterial blood gas is not required prior to randomization. 11. partial pressure of carbon dioxide (paco2) \> 65 mmhg on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. note that arterial blood gas is not required prior to randomization. 12. triplet or higher order multiple birth

Keywords: respiratory distress syndrome surfactant pre-term infant
iop measurements using ora after acxl in keratoconus

Conditions: IOP Readings Before and After Accelerated Corneal Collagen Crosslinking (CXL)

Summary: the investigators measured iop by goldmann applanation tonometry(gat) before and 6 months after accelerated 8 minutes cxl in using avedro kxl ,and correlated with corneal resistance factor(crf)using ora, ac angle and cct using scheimpflug imaging.


Eligibility criteria:
inclusion criteria: * kc patient indicated for cxl exclusion criteria: * advanced kc glaucoma patients
empowerment intervention for persons with young onset dementia

Conditions: Dementia; Empowerment

Summary: the purpose of this study is to evaluate the effects of an empowerment intervention for community-dwelling persons with young onset dementia and their informal caregivers.

this study focuses on the evaluation of an empowerment intervention developed for persons with young onset dementia and their informal caregivers. the empowerment intervention focuses on current capacities, maintenance of autonomy, and increasing the opportunities to feel useful. this pragmatic cluster randomized controlled trial aims to investigate (1) the effectiveness of the intervention concerning participants' well-being, quality of life, and behavioral issues, (2) the effect of the intervention on the informal caregivers' sense of competence and perceived distress, and (3) the impact of the intervention on healthcare costs. furthermore, the investigators aim to study the feasibility of the intervention to frame an implementation strategy. participants in the intervention group will receive the intervention for 5 months. participants of the control group receive care as usual.

Eligibility criteria:
inclusion criteria: * diagnosed with dementia before the age of 65 * living at home (community-dwelling) exclusion criteria: * dementia is caused by down's syndrome, huntington's disease, hiv or alcohol-related dementia. * limited contact between the person with dementia and the informal caregiver (\<3 times a week)

Keywords: daily activities
effect of early memantine administration on outcome of patients with moderate to severe traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: effect of early memantine administration on outcome of participents with moderate to severe traumatic brain injury

studying the effect of memantine on platelet, platelet/lymphocyte ratio (plr) and c reactive protein (crp) \& serum nse levels in participents with moderate to severe tbi as well as outcome. investigators evaluate prognostic effect of memantine on participents with moderate to severe tbi. also to estimate which of platelet, platelet/lymphocyte ratio (plr), c reactive protein (crp) or serum nse levels will be affected by administration of memantine in participents with moderate to severe tbi as a predictor of outcome.

Eligibility criteria:
inclusion criteria: * moderate to severe closed tbi with initial gcs of 4-12 * age from 18 to 65 years of both sexes * able to tolerate enteral feeding and drug administration within the first 24 hours of tbi. exclusion criteria: * open tbi or patients who would need open craniotomy later on. * comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours, acute or chronic renal insufficiency, hepatic diseases, autoimmune abnormalities, history of epileptic fits and known malignancies. patients with chest, cardiac, abdominal trauma or any other trauma requiring mechanical ventilation. patients with body mass index (bmi) \ 34.9 kg/m2.
self-adjusted nitrous oxide: a feasibility study in the setting of vasectomy

Conditions: Procedural Pain; Pain Catastrophizing; Procedural Anxiety

Summary: this study is being done to see if nitrous oxide during vasectomy decreases pain and anxiety, and also assess whether patients have better satisfaction when they control their own level of nitrous oxide during the procedure. if we find that patients experience less pain or anxiety with nitrous oxide, it could be suggested that self-adjusted nitrous oxide (sano) may be a useful tool for improving experience of care during vasectomy.

patients scheduled for vasectomy at beth israel deaconess medical center will be contacted and offered enrollment in the study. vasectomy will occur according to standard-of-care and all participants will receive the typical lidocaine injections at the beginning of the procedure. before the start of the vasectomy, a study staff member will help participants put on a plastic gas mask and demonstrate how to turn the gas up or down using the remote control. nitrous oxide and oxygen will be given through a plastic mask. a remote control given to participants will allow them to adjust the nitrous oxide based on their comfort. the nitrouseal® machine used in this study limits nitrous oxide to concentrations to "minimal sedation" (0-50%), which are levels where a person remains awake and is able to talk and breath normally. before the day of a participant's vasectomy, they will be asked questions related to demographics and medical history to determine study eligibility. immediately before and after vasectomy, participants will be asked to describe their anxiety and pain levels. at two-weeks and three-months after vasectomy, a brief electronic survey will be sent to participants' email asking about recollection of pain and anxiety and satisfaction with the procedure.

Eligibility criteria:
inclusion criteria: 1. scheduled for vasectomy 2. aged 21 to 85 years 3. suitable for receipt of inhaled nitrous oxide/oxygen 4. access to an email and computer exclusion criteria: 1. perioral facial hair impeding good mask seal 2. cognitive impairment that impedes ability to complete survey questions 3. intent to use benzodiazepines or opioids "as needed" for purposes of vasectomy 4. has any of the following medical conditions, which contraindicate use of nitrous oxide: 1. inner ear, bariatric or eye surgery within the last 2 weeks, 2. current emphysematous blebs, 3. severe b-12 deficiency, 4. bleomycin chemotherapy within the past year, 5. heart attack within the past year, 6. stroke within the past year, 7. class iii or higher heart failure.

Keywords: vasectomy nitrous oxide experience of care ambulatory